Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of phenoxyaromatic acids and compositions, which is applied in the field of pharmacy and can solve problems such as lack of blood lipids
Active Publication Date: 2009-08-26
SHENZHEN AUSA PHARM CO LTD +2
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0017] Examining the current clinical medication situation, there is no effective and safe drug for comprehensively controlling dyslipidemia, so it is urgent to develop a blood lipid-lowering drug that can comprehensively reduce LDL-C, TG, and TC levels and increase HDL-C levels , to solve the deficiencies of existing clinical drugs
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0037] Example 1 Preparation of Compound Fenofibrate Taurine Tablets (1000 Tablets)
[0046] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 300g of taurine and 200g of fenofibrate and mix uniformly according to the method of equal increments, add 160g of lactose, 50g of microcrystalline cellulose and 20g sodium carboxymethyl starch, mix uniformly according to the method of equal increments, add 10% povidone The aqueous solution is made into a soft material, granulated with a 20-mesh sieve, dried at 60°C for about 2 hours, granulated with a 20-mesh sieve, and the water cont...
Embodiment 2
[0047] Example 2 Preparation of Compound Bezafibrate Taurine Tablets (1000 Tablets)
[0056] The preparation method was the same as in Example 1, and each of the prepared compound tablets contained 100 mg of taurine and 400 mg of bezafibrate, and the mass ratio was 1:4.
Embodiment 3
[0057] Example 3 Preparation of Compound Taurine Gemfibrozil Tablets (1000 Tablets)
[0066] The preparation method was the same as in Example 1, and each tablet contained 100 mg of taurine and 400 mg of gemfibrozil in the prepared compound tablet, and the mass ratio was 1:4.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a composition capable of comprehensively improving blood lipid and insulin resistance state of a body at the same time, and belongs to the field of pharmacy. The composition comprises pharmaceutically acceptable doses of phenoxyaromatic acid drugs (including fenofibrate, bezafibrate, gemfibrozil, etc.) or pharmaceutically acceptable salts thereof, pharmaceutically acceptable doses of taurine and pharmaceutically acceptable carriers or excipients. The present invention also relates to that the composition is used to comprehensively control blood lipids of patients, including reducing total cholesterol (TC), low-density lipoprotein (LDL) and triglyceride (TG), and increasing high-density lipoprotein (HDL); simultaneously the present invention The composition involved can be used to treat metabolic syndrome, synergistically improve the insulin resistance state of the body, and improve the insulin sensitivity index, and its effect is obviously better than that of a single medicine. The present invention also relates to the application of the composition in the preparation of medicines for the treatment of living bodies with dyslipidemia or metabolic syndrome.
Description
technical field [0001] The invention relates to a composition containing phenoxyaromatic acid drugs and taurine, and the application of the composition in preparing medicines for treating dyslipidemia or metabolic syndrome (metabolic syndrome, MS). The present invention belongs to the field of pharmacy. Background technique [0002] Dyslipidemia refers to blood total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) exceeding the normal range and / or high-density lipoprotein cholesterol (HDL-C) below normal range. Dyslipidemia plays a very important role in the occurrence and development of atherosclerosis (AS) and the cardiovascular events (cardiovascular events, CVE) caused by it. one of the fastest growing fields. [0003] More and more research results show that dyslipidemia is one of the risk factors for coronary heart disease. The improvement of dyslipidemia can prevent or reverse the progression of atherosclerotic lesions, and can sig...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more